Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

348 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Machine learning to predict major bleeding during anticoagulation for venous thromboembolism: possibilities and limitations.
Mora D, Mateo J, Nieto JA, Bikdeli B, Yamashita Y, Barco S, Jimenez D, Demelo-Rodriguez P, Rosa V, Yoo HHB, Sadeghipour P, Monreal M; Registro Informatizado de Enfermedad TromboEmbólica (RIETE) Investigators. Mora D, et al. Among authors: barco s. Br J Haematol. 2023 Jun;201(5):971-981. doi: 10.1111/bjh.18737. Epub 2023 Mar 21. Br J Haematol. 2023. PMID: 36942630
Availability of medical and endovascular therapies for venous thromboembolism: a global survey for World Thrombosis Day.
Malerba SA, Fumagalli RM, Ay C, Cesarman-Maus G, De Paula EV, Dumantepe M, Guillermo Esposito MC, Hobohm L, Sadeghipour P, Samama CM, Sartori MT, Castellucci LA, Barco S; World Thrombosis Day Steering Committee. Malerba SA, et al. Among authors: barco s. J Thromb Haemost. 2024 Jan;22(1):255-262. doi: 10.1016/j.jtha.2023.10.002. Epub 2023 Oct 12. J Thromb Haemost. 2024. PMID: 37838241
Early switch to oral anticoagulation in patients with acute intermediate-risk pulmonary embolism (PEITHO-2): a multinational, multicentre, single-arm, phase 4 trial.
Klok FA, Toenges G, Mavromanoli AC, Barco S, Ageno W, Bouvaist H, Brodmann M, Cuccia C, Couturaud F, Dellas C, Dimopoulos K, Duerschmied D, Empen K, Faggiano P, Ferrari E, Galiè N, Galvani M, Ghuysen A, Giannakoulas G, Huisman MV, Jiménez D, Kozak M, Lang IM, Lankeit M, Meneveau N, Münzel T, Palazzini M, Petris AO, Piovaccari G, Salvi A, Schellong S, Schmidt KH, Verschuren F, Schmidtmann I, Meyer G, Konstantinides SV; PEITHO-2 investigators. Klok FA, et al. Among authors: barco s. Lancet Haematol. 2021 Sep;8(9):e627-e636. doi: 10.1016/S2352-3026(21)00203-9. Epub 2021 Aug 4. Lancet Haematol. 2021. PMID: 34363769 Clinical Trial.
Survival and quality of life after early discharge in low-risk pulmonary embolism.
Barco S, Schmidtmann I, Ageno W, Anušić T, Bauersachs RM, Becattini C, Bernardi E, Beyer-Westendorf J, Bonacchini L, Brachmann J, Christ M, Czihal M, Duerschmied D, Empen K, Espinola-Klein C, Ficker JH, Fonseca C, Genth-Zotz S, Jiménez D, Harjola VP, Held M, Iogna Prat L, Lange TJ, Lankeit M, Manolis A, Meyer A, Münzel T, Mustonen P, Rauch-Kroehnert U, Ruiz-Artacho P, Schellong S, Schwaiblmair M, Stahrenberg R, Valerio L, Westerweel PE, Wild PS, Konstantinides SV; HoT-PE Investigators; HoT-PE Trial Investigators are:. Barco S, et al. Eur Respir J. 2021 Feb 4;57(2):2002368. doi: 10.1183/13993003.02368-2020. Print 2021 Feb. Eur Respir J. 2021. PMID: 32859673 Free article.
Early discharge and home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban: an international multicentre single-arm clinical trial.
Barco S, Schmidtmann I, Ageno W, Bauersachs RM, Becattini C, Bernardi E, Beyer-Westendorf J, Bonacchini L, Brachmann J, Christ M, Czihal M, Duerschmied D, Empen K, Espinola-Klein C, Ficker JH, Fonseca C, Genth-Zotz S, Jiménez D, Harjola VP, Held M, Iogna Prat L, Lange TJ, Manolis A, Meyer A, Mustonen P, Rauch-Kroehnert U, Ruiz-Artacho P, Schellong S, Schwaiblmair M, Stahrenberg R, Westerweel PE, Wild PS, Konstantinides SV, Lankeit M; HoT-PE Investigators. Barco S, et al. Eur Heart J. 2020 Jan 21;41(4):509-518. doi: 10.1093/eurheartj/ehz367. Eur Heart J. 2020. PMID: 31120118 Clinical Trial.
Enoxaparin for primary thromboprophylaxis in symptomatic outpatients with COVID-19 (OVID): a randomised, open-label, parallel-group, multicentre, phase 3 trial.
Barco S, Voci D, Held U, Sebastian T, Bingisser R, Colucci G, Duerschmied D, Frenk A, Gerber B, Götschi A, Konstantinides SV, Mach F, Robert-Ebadi H, Rosemann T, Simon NR, Spechbach H, Spirk D, Stortecky S, Vaisnora L, Righini M, Kucher N; OVID investigators. Barco S, et al. Lancet Haematol. 2022 Aug;9(8):e585-e593. doi: 10.1016/S2352-3026(22)00175-2. Epub 2022 Jun 30. Lancet Haematol. 2022. PMID: 35779558 Free PMC article. Clinical Trial.
348 results